This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to
About the Federal Register
on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.
Notice
Enter a search term or FR citation e.g.
88 FR 38230 FR 78782024-13208USDA09/05/24RULE0503-AA39SORN
Choosing an item from
full text search results
will bring you to those results. Pressing enter in the search box
will also bring you to search results.
Choosing an item from
suggestions
will bring you directly to the content.
Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 16, 2026 will be considered.
Table of Contents
Enhanced Content - Table of Contents
This table of contents is a navigational tool, processed from the
headings within the legal text of Federal Register documents.
This repetition of headings to form internal navigation links
has no substantive legal effect.
Document page views are updated periodically throughout the day and are
cumulative counts for this document. Counts are subject to sampling,
reprocessing and revision (up or down) throughout the day.
Page views
140
as of
10/09/2026 at 2:15 am EDT
Other Formats
Enhanced Content - Other Formats
This document is also available in the following formats:
This PDF is FR Doc. 2026-03994 as it appeared on Public Inspection on
02/26/2026 at 8:45 am.
It was viewed
11
times while on Public Inspection.
If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507.
Learn more here.
Published Document: 2026-03994 (91 FR 9875)
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
National Institutes of Health, HHS.
ACTION:
Notice.
SUMMARY:
The Clinical Center of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice to Bionic Power Inc., a company organized in British Columbia, Canada.
DATES:
Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before March 16, 2026 will be considered.
ADDRESSES:
Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Edward Fenn, Senior Technology Transfer Manager, NCI Technology Transfer Center, Telephone: (240)-276-6833; Email
Tedd.Fenn@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property
1. US Provisional Patent Application No. 62/368,926 filed July 29, 2016, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-096-2016-0-US-01];
2. International PCT Application No. PCT/US2017/044625 filed July 31, 2017, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-096-2016-0-PCT-02];
3. US Patent No. 11,801,153 issued 10/31/2023, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-096-2016-0-US-03];
4. US Patent Application No. 18/243,573, filed 9/7/2023, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-096-2016-0-US-04];
5. US Provisional Patent Application No. 63/539,898 filed September 22, 2023, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-241-2023-0-US-01];
6. International PCT Application No. PCT/US2024/047743 filed September 20, 2024, and entitled “Powered Gait Assistance Systems” [HHS Reference No. E-241-2023-PCT-02];
The patent rights in these inventions have been assigned to the Government of the United States of America.
The prospective exclusive license territory may be worldwide where patent rights exist and the field of use may be limited to the following:
“For the treatment of human movement disorders.”
The subject technologies relate to systems, methods, and devices for powered gait assistance—that may be integrated to comprise a wearable orthosis (for example a powered exoskeletal device) that attaches to the leg of a user who has a movement disorder, such as a gait disorder. The technologies can augment and provide assistance and training for improvements to walking. The system can detect movements, such as gait phases and adjust torque in real time to provide assistive torque during stance and resistive torque during training to improve strength and movement mechanics of the user. For example, it can provide assistance with gait movement for patients with knee extension deficits in conditions such as crouch gait in cerebral palsy, or spina bifida, stroke and other movement disorders).
( printed page 9876)
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license that are timely filed in response to this notice will be treated as objections to the grant of the contemplated exclusive patent license. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.
Dated: February 25, 2026.
Richard U. Rodriguez,
Supervisory Technology Transfer and Patent Specialist, Technology Transfer Center, National Cancer Institute.